SCHEMBL6602480

SCHEMBL6602480

Nc1nc(N)c(F)[c]c1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6600024 0.85
SCHEMBL6003621 0.65 NQO1 (0.30)
SCHEMBL6003760 0.65 REV1 (0.30)
SCHEMBL10414868 0.64 NQO1 (0.50)
SCHEMBL6003429 0.62 AXL (0.30)
SCHEMBL5508757 0.62
SCHEMBL14166403 0.60 NQO1 (0.39)
SCHEMBL20449075 0.58 LMNA (0.36)
SCHEMBL21051215 0.58
SCHEMBL2889730 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1396491-A2 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors Novartis AG (CH) 2004-03-10 EP disclosed
US-6300347-B1 FOR THERAPY OF TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 MEDIATED DISEASES SUCH AS RHEUMATOID ARTHRITIS AND DISEASES OF BONE METABOLISM, E.G. OSTEOPOROSIS NOVARTIS AG (CH) 2001-10-09 US disclosed